board supervisory board historystart up phase technology commercialization product development awards contactmedia and investors business development innovation capital careers drug safety pipelinemorphosys s therapeutic pipeline clinical development expertiseclinical development drug safety regulatory affairs quality assurance proprietary portfoliomor208 mor202 mor103 gsk3196165 mor209 es414 mor106 mor107 partnered programs lighthouse projectsguselkumab anetumab ravtansine gantenerumab active clinical trialsmor208 mor202 mor103 gsk3196165 mor209 es414 mor106 scienceengineering the medicines of tomorrow scientific research expertisediscovery alliances and technologies protein sciences preclinical development main research areascancer immuno oncology inflammatory and autoimmune diseases antibodies targeting gpcrs lanthipeptides drug development capabilitiesdisease biology and target validation technologies drug discovery and optimization drug profiling and assay development production and cmc regulatory affairs preclinical development clinical development publications partneringmorphosys as a partner partnering expertisebusiness development alliance management existing partnerships partnering opportunitiesearly stage mid stage late stage technology contact innovation capitalinnovation capital investment approach portfolio companies contact media and investorsinvest in the medicines of tomorrow stock informationgeneral information stock charts share price performance shareholder structure analysts adr share buy back media centercorporate releases ad hoc releases presentations pictures social media presence investor informationfinancial guidance fundamentals business segments financial reports presentations info request morphosys eventscompany calendar upcoming conferences conferences and webcasts corporate governancedeclaration about corporate management declaration of conformity compensation managers transactions annual general meetinglatest agm agm archive contact careerscareers working at morphosys compensation and benefits job opportunities information for students show hide menu engineering the medicines of tomorrow learn how morphosys approaches drug development . more info hematological cancers affect adults and children alike . morphosys is developing several blood cancer programs . more info antibody drugs have transformed the way inflammatory and autoimmune diseases are treated today . morphosys is exploring new approaches to continue this success . more info solid tumors can occur in several organs of the human body . morphosys and its partners are working on a broad portfolio of new therapies . more info morphosys s vision morphosys is committed to developing exceptional new treatments for patients suffering from serious diseases . a leader in the field of therapeutic antibodies today morphosys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry . learn more about the company august 01 2016 webcast half year report full details half year report2016 see our q2 report morphosys on twitter visit us on twitter latest news 01 10 2016 morphosys announces that its licensee janssen reports positive results ... read media release 29 09 2016 morphosys and galapagos start first in patient dosing of il 17c antibody ... read media release 19 09 2016 lanthio pharma expands management team read media release 12 09 2016 morphosys appoints four r & d experts to its newly formed scientific ... read media release 06 09 2016 morphosys initiates phase 2 3 trial of cd19 antibody mor208 plus ... read media release 03 08 2016 morphosys successfully completes safety run in of mor208 in l mind ... read media release 01 08 2016 morphosys ag reports results for the first six months of 2016 read media release 04 07 2016 morphosys receives clinical milestone for start of phase 1 trial in ... read media release 17 06 2016 morphosys reports publication of clinical case report of a blood cancer ... read media release 06 06 2016 morphosys presents updated clinical data for mor202 in multiple myeloma ... read media release therapeutic pipeline morphosys has established one of the broadest pipelines in the biopharmaceutical industry . pipeline media and investors morphosys is driven by the ambition to create the most valuable pipeline of biopharmaceuticals in the industry . media and investors partnering opportunities collaborations are a main component of our strategy . we are open to discuss deal structures where we can contribute to the development of novel drugs in a significant way . partnering opportunities drug development capabilities morphosys is dedicated to become a fully integrated biopharmaceutical company including late stage clinical development and marketing co promotion of its own drugs . drug development capabilities leading antibody technologies morphosys has made hucal and its successor technology ylanthia into reliable sources of therapeutic antibody candidates . leading antibody technologies proprietary program mor208 when blood formation leads to cancer the cd19 antibody mor208 is currently being evaluated in all cll and nhl . mor208 antibody backgrounder antibodies are essential to life . today these molecules are used as therapeutic agents for the treatment of severe diseases . antibody backgrounder proprietary program mor209 together with emergent biosolutions morphosys is developing a new way to fight prostate cancer . mor209 lighthouse project gantenerumab is being developed by roche for alzheimer s desease . gantenerumab 2016 morphosys ag imprint privacy policy contact address morphosys ag lena christ str . 48 82152 martinsried planegg germany phone 49 89 899 27 0 fax 49 89 899 27 222 e mail info morphosys.com companystrategy management pipelinemor208 mor202 mor103 gsk3196165 mor209 es414 mor106 mor107 clinical trials media and investorsstock information media center investor information events careersworking at morphosys compensation and benefits job opportunities information for students